Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for prophylaxis of intestinal acute graft-versus-host disease after allogeneic HSCT
jRCT2080224160Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in acute gastrointestinal graft-versus-host disease (aGI-GVHD) and graft-versus-host disease (GVHD) comparing Vedolizumab arm with Placebo arm (2 arms). Started Nov 2018; status: completed.
02
Drugs
vedolizumab
03
Conditions
acute gastrointestinal graft-versus-host disease (aGI-GVHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on jRCT2080224160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224160.